ANN ARBOR, Mich., Sept. 13, 2023 /PRNewswire/ -- Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), will be participating at the Stifel I&I summit, held virtually, from September 19 - 20, 2023..

密歇根州安阿伯市，2023年9月13日/PRNewswire/-吊带治疗公司，一家专注于治疗甲状腺眼病（TED）的口服小分子晚期开发的生物制药公司将参加在几乎从2023年9月19日至20日举行的Stifel I＆I峰会上。。

Ryan Zeidan, Ph.D., Chief Executive Officer of Sling Therapeutics, will present a company presentation on September 19, at 12:45 p.m. ET.

Sling Therapeutics首席执行官Ryan Zeidan博士将于9月19日下午12:45发表公司演讲。

About Sling TherapeuticsSling Therapeutics, Inc., is a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED). The company is advancing the evaluation of its lead product candidate, linsitinib, in a Phase 2b clinical trial based on extensive preclinical and clinical data.

关于Sling TherapeuticsSling Therapeutics，Inc。是一家生物制药公司，专注于口服小分子的后期开发，用于治疗甲状腺眼病（TED）。该公司正在基于广泛的临床前和临床数据，在2b期临床试验中推进对其主要候选产品linsitinib的评估。

Linsitinib offers the potential of a convenient oral small molecule that could significantly reduce the treatment burden for people living with TED. For more information visit https://slingtx.com/. .

Linsitinib提供了一种方便的口服小分子的潜力，可以显着减轻TED患者的治疗负担。欲了解更多信息，请访问https://slingtx.com/. .

Investor ContactJessica VoGilmartin Group, LLC[email protected]

投资者联系Jessica VoGilmartin Group，LLC[电子邮件保护]

Media ContactAdam DaleyBerry & Company Public Relations212.253.8881[email protected]

媒体联系Adam DaleyBerry＆Company公共关系212.253.8881[电子邮件保护]

SOURCE Sling Therapeutics

源吊带疗法